ABSCF:OTC-AB Science S.A (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 11.90

Change

0.00 (0.00)%

Market Cap

USD 0.56B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AB Science S.A (ABSCF) Stock Analysis:
Based on the AB Science S.A stock forecasts from 0 analysts, the average analyst target price for AB Science S.A is not available over the next 12 months. AB Science S.A’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AB Science S.A is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, AB Science S.A’s stock price was USD 11.90. AB Science S.A’s stock price has changed by +0.00% over the past week, +7.21% over the past month and -30.57% over the last year.

No recent analyst target price found for AB Science S.A
No recent average analyst rating found for AB Science S.A

About

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical tria ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

-0.69 (-1.99%)

USD73.18B 23.07 13.39
MKGAF MERCK Kommanditgesellschaft au..

+6.61 (+3.91%)

USD72.39B 23.13 13.39
TKPHF Takeda Pharmaceutical Company ..

-0.18 (-0.63%)

USD44.38B 13.31 0.07
SGIOF Shionogi & Co. Ltd

-1.05 (-1.94%)

USD16.38B 21.89 0.11
SGIOY Shionogi & Co. Ltd

-0.24 (-1.77%)

USD16.34B 21.86 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

+0.02 (+0.48%)

USD15.23B 16.86 2.67
ESALF Eisai Co. Ltd

+0.08 (+0.19%)

USD12.34B 27.58 0.10
ESALY Eisai Co. Ltd

-0.16 (-0.37%)

USD12.29B 27.77 0.10
GNHAF Vifor Pharma AG

N/A

USD11.59B 78.36 17.10
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ABSCF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.99% 69% D+ 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.99% 67% D+ 52% F
Trailing 12 Months  
Capital Gain -30.57% 75% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.57% 74% C 43% F
Trailing 5 Years  
Capital Gain -3.33% 66% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.33% 64% D 51% F
Average Annual (5 Year Horizon)  
Capital Gain 30.67% 62% D- 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.67% 61% D- 64% D
Risk Return Profile  
Volatility (Standard Deviation) 84.50% 53% F 36% F
Risk Adjusted Return 36.30% 74% C 61% D-
Market Capitalization 0.56B 85% B 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -32.46 89% B+ 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 136.01% 93% A 95% A
Return on Assets -33.98% 34% F 20% F
Debt to Equity Ratio -28.83% 81% B- 90% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.83 54% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector